We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
- Authors
Esserman, Laura J; Berry, Donald A; DeMichele, Angela; Carey, Lisa; Davis, Sarah E; Buxton, Meredith; Hudis, Cliff; Gray, Joe W; Perou, Charles; Yau, Christina; Livasy, Chad; Krontiras, Helen; Montgomery, Leslie; Tripathy, Debasish; Lehman, Constance; Liu, Minetta C; Olopade, Olufunmilayo I; Rugo, Hope S; Carpenter, John T; Dressler, Lynn; Chhieng, David; Singh, Baljit; Mies, Carolyn; Rabban, Joseph; Chen, Yunn-Yi; Giri, Dilip; van 't Veer, Laura; Hylton, Nola
- Abstract
Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter breast cancer study integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and their relationship and predictability based on tumor biomarkers.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 26, p3242
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.39.2779